{"authors": [["Al-Huniti", "N", "N", "Quantitative Clinical Pharmacology, Early Clinical Development, Innovative Medicine and Early Development, AstraZeneca, Waltham, MA, USA."], ["Petersson", "K", "K", "qPharmetra, LLC, Stockholm, Sweden."], ["Tang", "W", "W", "Quantitative Clinical Pharmacology, Early Clinical Development, Innovative Medicine and Early Development, AstraZeneca, Waltham, MA, USA."], ["Masson", "E", "E", "Quantitative Clinical Pharmacology, Early Clinical Development, Innovative Medicine and Early Development, AstraZeneca, Waltham, MA, USA."], ["Li", "J", "J", "Quantitative Clinical Pharmacology, Early Clinical Development, Innovative Medicine and Early Development, AstraZeneca, Waltham, MA, USA."]], "text": "", "id": "29274100", "date": "2017-12-22", "title": "Population exposure-safety analysis of cediranib for Phase I and II studies in patients with cancer.", "doi": "10.1111/bcp.13495", "journal": ["British journal of clinical pharmacology", "Br J Clin Pharmacol"]}